A role for intracellular immunization in chemosensitization of tumor cells?

Gene Therapy

Volumn 6, Issue 7, 1999, Pages 1202-1209

  Piche A ^a   Rancourt, C ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Cancer; Chemosensitivity; Drug resistance; Gene therapy; Intracellular immunization

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; CELL PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; RAS PROTEIN; RIBOZYME;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNIZATION; ONCOGENE C ERB; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANTIBODIES, MONOCLONAL; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; IMMUNIZATION, PASSIVE; INTRACELLULAR FLUID; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RNA, CATALYTIC;

EID: 0032774070     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300952     Document Type: Review

References (119)

1. Godwin AK et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070-3074.
2. Scanlon KJ et al. Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 1989; 9: 1311-1312.
3. Andrews PA, Howell SB. Cellular pharmocology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990; 2: 35-13.
4. Minagawa Y et al. Enhanced topoisomerase I activity and increased topoisomerase II content in displatin-resitant cancer cell lines. Jpn J Cancer Res 1997; 88: 1218-1223.
5. Drlica K, Franco RJ. Inhibitors of DNA topoisomerases. Biochemistry 1988; 27: 2253-2259.
6. Goldstein LJ et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.
7. Fojo A, Hamilton TC, Young RC, Ozols RF. Multidrug resistance in ovarian cancer. Cancer 1987; 60 (Suppl. 8): 2075-2080.
8. Chan HS et al. A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines. Lab Invest 1989; 59: 870-875.
9. Chan HS et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Engl J Med 1991; 325: 1608-1614.
10. Pirker R et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-712.
11. Marie JP, Zittoun R, Sikic BI. Multidrug resitance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-592.
12. Campos L et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphagocytic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
13. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 P-glycoprotein gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992; 84: 1486-1491.
14. Goasguen JE et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394-2398.
15. Fisher DE. Apoptosis in cancer therapy. Cell 1994; 78: 539-542.
16. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-546.
17. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin North Am 1995; 9: 451-473.
18. Eliopoulos AG et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995; 11: 1217-1228.
19. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.
20. Nguyen DM et al. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996; 112: 1372-1377.
21. Pirollo KF et al. P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735-1746.
22. Chang F, Syrjanem S, Syrjanem K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-1022.
23. Warenius HM, Seabra LA, Maw P. Sensitivity to cis-diammine-dichloroplatinum in human cancer cells is related to expression of cyclin D1 but no c-Raf-1 protein. Int J Cancer 1996; 67: 224-231.
24. Hochhauser D et al. Effect of cyclin D1 overexpression on drug sensitivity in human fibrosacrcoma cell line. J Natl Cancer Inst 1996; 88: 1269-1275.
25. Baserga R. Oncogenes and the strategy of growth factors. Cell 1994; 79: 927-930.
26. Meyn RE, Stephens LC, Milas L. Programmed cell death and radioresistance. Cancer Metast Rev 1996; 15: 119-131.
27. Dickstein B et al. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 1993; 157: 110-118.
28. Vicker PJ, Dickson RB, Shoemaker R, Cowan KH. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 1988; 2: 886-892.
29. Gusterson BA et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-1056.
30. Bergmann C, Hung M, Weinberg R. The neu oncogene encodes an epidermal growth factor receptor related protein. Nature 1986; 319: 226-229.
31. Berchuck A et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
32. Felip E et al. Overexpression of c-erbB-2 in epithelial ovarian cancer, prognostic value and relationship with response to chemotherapy. Cancer 1995; 75: 2147-2152.
33. Tsai CM et al. Enhanced chemoresistance by elevation of p185neu levels in HER/neu-transfected human lung cancer cells. J Natl Cancer Inst 1995; 87: 682-684.
34. Tsai CM, Chang KT, Perng RP. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993; 85: 897-901.
35. Baltimore D. Gene therapy: intracellular immunization. Nature 1988; 335: 395-396.
36. Aslaro FK, McDonnell WM. Antisense-oligonucleotide therapy. New Engl J Med 1995; 334: 316-318.
37. James HA, Gibson I. The therapeutic potential of ribozymes. Blood 1997; 91: 371-382.
38. Marasco W. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Therapy 1997; 4: 11-15.
39. Chert S-Y, Marasco WA. Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol 1996; 23: 148-153.
40. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293-299.
41. Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies form their genes. Immunol Rev 1992; 130: 41-68.
42. Bergmann C, Hung M, Weinberg R. The neu oncogene encodes an epidermal growth factor receptor related protein. Nature 1986; 319: 226-229.
43. Berchuck A et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
44. Barnes MN et al. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemo-sensitivity. Clin Cancer Res 1996; 2: 1089-1095.
45. Paik S. Clinical significance of erbB-2 (HER-2/neu) protein. Cancer Invest 1992; 10: 575-579.
46. Hancock MC et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-4580.
47. Deshane J et al. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Therapy 1994; 1: 332-337.
48. Deshane J et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1995; 96: 2980-2989.
49. Deshane J et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 1995; 59: 8-14.
50. Deshane J et al. Intracellular antibody directed against erbB-2 mediated targeted tumor cell eradication by inducing apoptosis. Cancer Gene Ther 1996; 3: 89-98.
51. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Molec Cell Biol 1995; 15: 1182-1191.
52. Fantl WJ, Johson DE, Williams LT. Signalling by receptor tyrosine kinases. Ann Rev Biochem 1993; 62: 453-481.
53. Salomon DS, Brandt R, Ciardello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 1995; 19: 183-232.
54. Murphy LC et al. Epidermal growth factor: receptor and ligand expression in human breast cancer. Semin Cancer Biol 1990; 1: 305-315.
55. Murray PA et al. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 1993; 67: 1408-1412.
56. Aboud-Pirak E et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988; 80: 1605-1611.
57. Fan Z, Baselga J, Massui H, Mendelsohn J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografs. Cancer Res 1993; 53: 4637-4642.
58. Baselga J et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-1333.
59. Peng D et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996; 56: 3666-3669.
60. Jannot CB et al. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 1996; 13: 275-282.
61. Beerli RR, Wels W, Hynes NE. Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophy Res Commun 1994; 204: 666-672.
62. Krajewski S et al. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 1997; 3: 199-208.
63. Doglioni C et al. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates with particular reference to estrogen receptor status. Virchows Arch 1994; 424: 47-51.
64. Nakasu S et al. bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 1994; 88: 520-526.
65. Alderson LM et al. Human gliomas with wild-type p53 express bcl-2. Cancer Res 1995; 55: 999-1001.
66. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995; 146: 20-26.
67. Xerri L et al. Predominant expression of the long isoform of Bcl-X in human lymphomas. Br J Haematol 1996; 92: 900-907.
68. Sclaifer D et al. High expression of the Bcl-X gene in Reed-Sternberg cells of Hodgkin's disease. Blood 1995; 85: 2671-2677.
69. Krajewski M et al. Elevated expression of Bcl-X and reduced BAK in primary colorectal carcinoma. Cancer Res 1996; 56: 2422-2429.
70. Krajewski M et al. Immunohistochemical analysis of Bcl-2, BAX, Bcl-X and MCL-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-1575.
71. Krajewski S et al. Immunohistochemical analysis of Bcl-2, Bcl-X, MCL-1 and BAX in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-814.
72. Tu Y et al. Bcl-x expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998; 58: 256-262.
73. Grim JE et al. A family of plasmid vectors for the intracellular expression of single-chain antibodies. Gene (Submitted).
74. Piche A et al. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998; 58: 2134-2140.
75. Piche A et al. Modulation of drug-induced apoptosis by anti-Bcl-2 single-chain antibodyin ovarian cancer cells. Tumor Targeting 1998; 3: 147-155.
76. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
77. Mills NE et al. Increased prevalence of K-ras oncogene mutations in lung adenocarcinomas. Cancer Res 1995; 55: 1444-1447.
78. ras protein. FEBS Lett 1990; 274: 193-198.
79. Cochet O et al. Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression. Cancer Res 1998; 58: 1170-1176.
80. Nooter K et al. Constitutive expression of the c-Ha-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcome cell line. Br J Cancer 1995; 71: 556-561.
81. Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 1997; 13: 27-33.
82. Hoedemaeker FJ et al. A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219. J Biol Chem 1997; 47: 29784-29789.
83. Pines J. Protein kinases and cell cycle control. Semin Cell Biol 1994; 5: 399-408.
84. Motokura T, Arnold A. Cyclins and oncogenesis. Biochem Biophys Acta 1993; 1155: 63-78.
85. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68: 67-108.
86. Arnold A et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989; 83: 2034-2040.
87. Bellacosa A et al. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996; 2: 175-180.
88. Poul M-A, Teyssier C, Lefranc M-P. Inhibition of cyclin D1 oncogene with intracellular single chain antibodies. Exploring and exploiting antibody and Ig superfamily combining sites. Keystone Symposia, New Mexico, 22-28 February, 1996.
89. Wu L, Wu A, Jiang K. Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells. Chung Hua Fu Can Ko Tsa Chih 1996; 31: 169-172.
90. Brader KR, Wolf JK, Chakrabarty S, Price JE. Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol Res 1998; 5: 1269-1274.
91. Grandis JR et al. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997; 15: 409-416.
92. He YK et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998; 90: 1080-1087.
93. Dixit M et al. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst 1997; 89: 365-373.
94. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998; 101: 344-352.
95. Driscoll B et al. Cyclin D-1 antisense RNA destablilizes PRB and retards lung cancer cell growth. Am J Physiol-Lung Cell & Mol Physiol 1997; 17: 941-949.
96. Zhou P et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of eosphagal cancer cells. Oncogene 1995; 11: 571-580.
97. Arber N et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997; 57: 1569-1574.
98. Keith FJ, Bardbury DA, Ahu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995; 9: 131-138.
99. Jansen B et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 1998; 4: 232-234.
100. Arteaga CL, Holt JT. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res 1996; 56: 1098-1103.
101. Aoki K, Yoshida T, Sugimura T, Terada M. Liposme-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-3816.
102. Holt JT, Arteaga CL, Roberston D, Moses HL. Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Hum Gene Ther 1996; 7: 1367-1380.
103. Bunnell BA, Morgan RA. Gene Therapy for AIDS. Mol Cell 1996; 1: 1-12.
104. Kobayashi H, Dorai T, Hooland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 1994; 54: 1271-1275.
105. Kiehntopf M et al. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 1994; 13: 4645-4646.
106. Dorai T, Olsson CA, Katz AE, Buttyan R. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate 1997; 32: 246-258.
107. Dorai T, Goluboff ET, Olsson CA, Buttyan R. Development of a hammerhead ribozyme against Bcl-2. 2. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 1997; 17: 3307-3312.
108. Rancourt C et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simple virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4: 2455-2461.
109. Gu D et al. Retargeting adenovirus vectors with FGF-2 leads to enhanced efficacy and decreased toxicity. Proc Am Assoc Cancer Res 1998; 39: 512.
110. Feng M et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnol 1997; 15: 866-870.
111. Johnston KM et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8: 359-370.
112. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
113. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
114. Chen CY et al. Effect of herpes simplex thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the 'bystander effect'. Hum Gene Ther 1995; 6: 1467-1476.
115. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697-2702.
116. Fujiwara T et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthoptic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-1462.
117. Pirollo KF et al. p53-mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735-1746.
118. Frank DK, Frederick MJ, Liu T-J, dayman GL. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin Cancer Res 1998; 4: 2521-2527.
119. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998; 4: 1393-1403.